Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Minimal Residual Disease
57%
NPM1
50%
Chemotherapy
41%
Low Drug Dose
33%
Intensive Care
33%
Cytarabine
33%
Phase II Trials
33%
Venetoclax
33%
False Positive Result
16%
Clinical Trial
13%
Morphology
11%
Quality of Life
11%
Arm
11%
Disease Exacerbation
9%
Genetics
8%
Morbidity
8%
Core Binding Factor Beta
8%
Patient Safety
8%
Granulocyte
8%
Survival Time
5%
Adaptive Clinical Trial
5%
Event Free Survival
5%
Experimental Therapy
5%
Supportive Care
5%
Outpatient
5%
Survival Rate
5%
Spontaneous Remission
5%
Health Care Cost
5%
Pharmacology, Toxicology and Pharmaceutical Science
Minimal Residual Disease
33%
Chemotherapy
33%
Acute Myeloid Leukemia
33%
Remission
13%
Disease Exacerbation
13%
Recurrence Free Survival
6%
Nursing and Health Professions
Minimal Residual Disease
33%
Acute Myeloid Leukemia
33%
Remission
13%
Disease Exacerbation
13%
Salvage Therapy
6%
Recurrence Free Survival
6%
